Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial

Lancet

Volumn 362, Issue 9395, 2003, Pages 1517-1526

  Zajicek, John ^a   Fox, Patrick ^a   Sanders, Hilary ^b   Wright, David ^b   Vickery, Jane ^a   Nunn, Andrew ^c   Thompson, Alan ^d  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

^c Med Res Cncl Clinical Trials Unit   (United Kingdom)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; CANNABIS; DRONABINOL; PLACEBO;

ACUTE STRESS DISORDER; ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAND MAL SEIZURE; HUMAN; INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE FATIGUE; MUSCLE SPASM; MUSCLE STIFFNESS; PAIN; PARESTHESIA; PATIENT SELECTION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SPASTICITY; STATISTICAL ANALYSIS; TREMOR; URINARY TRACT INFECTION; VERTIGO; VISUAL DISORDER; XEROSTOMIA;

EID: 0242654882     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14738-1     Document Type: Article

References (37)

1. Paty D.W., Ebers G.C. Multiple sclerosis. 1998;FA Davis, Philadelphia.
2. Hinson J.C., Boone T.B. Urodynamics and multiple sclerosis. Urolog Clin N Am. 23:1996;475-481.
3. Sliwa J.A. Upper urinary tract abnormalities in multiple sclerosis. Arch Phys Med Rehab. 77:1996;247-251.
4. Eisenberg D.M., Davis R.B., Ettner S.L., et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 280:1998;1569-1575.
5. Schwartz C.E., Laitin E., Brotman S., LaRocca N. Utilisation of unconventional treatments by persons with MS: is it alternative or complementary? Neurology. 52:1999;626-629.
6. Consroe P., Musty R., Rein J., Tillery W., Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol. 38:1997;44-48.
7. Cannabis: the scientific and medical evidence (9th report). 1998;Stationery Office, London.
8. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
9. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
10. Devane W.A., Hanus L., Breuer A., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
11. Panikashvili D., Simeonidou C., Ben-Shabat S., et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 413:2001;527-531.
12. Thompson A.J., Baker D. Cannabinoids in MS: potentially useful but not just yet! Neurology. 58:2002;1323-1324.
13. Petro D.J., Ellenberger C. Jr. Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol. 21:1981;413S-416S.
14. Ungerleider J.T., Andyrsiak T., Fairbanks L., Ellison G.W., Myers L.W. Delta 9 THC in the treatment of spasticity associated with multiple sclerosis. Adv Alc Sub Abuse. 7:1987;39-50.
15. Greenberg H.S., Werness S.A., Pugh J.E., Andrus R.O., Anderson D.J., Domino E.F. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther. 55:1994;324-328.
16. Killestein J., Hoogervorst E.L., Reif M., et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 58:2002;1404-1407.
17. Evans S.J.W., Day S.J., Royston P. MINIM: minimisation program for allocating patients to treatments in clinical trials, Version 1.5. 1990;London Hospital Medical College, London.
18. Begg C., Iglewitz B. A treatment allocation procedure for sequential clinical trials. Biometrics. 36:1980;81-90.
19. Pocock S.J., Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 31:1975;103-115.
20. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner. 192:1964;540-542.
21. Collen F.M., Wade D.T., Bradshaw C.M. The Rivermead mobility index: a further development of the Rivermead motor assessment. Int Disabil Stud. 13:1991;50-54.
22. Sharrack B., Hughes R.A. The Guy's neurological disability scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler. 5:1999;223-233.
23. Mahoney F.I., Barthel D.W. Functional evaluation: the Barthel Index. Md State Med J. 14:1965;61-65.
24. Goldberg D., Williams P. A user's guide to the General Health Questionnaire. 1991;NFER-Nelson, Windsor.
25. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
26. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology. 44:1994;S70-S78.
27. Smith C., Birnbaum G., Carter J.L., Greenstein J., Lublin F.D. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. Neurology. 44:1994;S34-S42.
28. Hobart J., Thompson A. Measurement of neurological outcomes. Goadsby P.J., McArthur J.C., McDonald W.I., Ashbury A.K., McKhann G.M. Diseases of the nervous system: clinical neuroscience and therapeutic principles. 3rd edn :2002;Cambridge University Press, Cambridge.
29. Riazi A., Fox P., Vickery J., Thompson A. J., Zajicek J., Hobart J.C. Developing a patient-based measure of the impact of spasticity in multiple sclerosis. Multiple Sclerosis ECTRIMS. 9:2003;S151-S152.
30. Nuyens G., De Weerdt W., Ketalaer P., et al. Interrater reliability of the Ashworth scale in multiple sclerosis. Clinical Rehabilitation. 8:1994;286-292.
31. Vaney C., Heinzel-Gutenbrunner M., Jobin P., et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomised, double-blind, placebo-controlled, crossover study. Multiple Sclerosis ECTRIMS. 9:2003;S14.
32. Campbell F.A., Tramer M.R., Carroll D., Reynolds D.J., Moore R.A., McQuay H.J. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ. 323:2001;13-16.
33. Iversen L. Cannabis and the brain. Brain. 126:2003;1252-1270.
34. Rog D., Young C.A. Randomised controlled trial of cannabis-based medicinal extracts in the treatment of neuropathic pain due to multiple sclerosis. Multiple Sclerosis ECTRIMS. 9:2003;S25.
35. Arevalo-Martin A., Vela J.M., Molina-Holgado E., Borrell J., Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci. 23:2003;2511-2516.
36. Shakespeare D.T., Boggild M., Young C. Anti-spasticity agents for multiple sclerosis (Cochrane Review), Issue 3. The Cochrane Library. 2003;Update Software, Oxford.
37. Wiffen P., Collins S., McQuay H., Carroll D., Jedad A., Moore A. Anticonvulsant drugs for acute and chronic pain (Cochrane Review). The Cochrane Library, Issue 3. 2003;Update Software, Oxford.